News

November 30, 2018

First Patient Dosed in Phase 3 Trial of BeiGene’s Zanubrutinib for Hard-to-Treat Leukemia, Lymphoma

News

The global Phase 3 trial evaluating BeiGene’s investigational Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has started dosing patients. The study (NCT03734016) is recruiting patients who failed ... Read more

November 28, 2018December 1, 2018

Leukemia & Lymphoma Society Funding Next Wave of Blood Cancer Research

News

The Leukemia & Lymphoma Society (LLS) has announced $42 million in new grants for 80 disease research teams globally, in its continuing efforts to invest in comprehensive blood cancer research. More ... Read more

November 27, 2018

Opdivo Halts Hodgkin’s Progression in Those Who Earlier Had Achieved Remission, Study Shows

News

Re-treatment with Opdivo (nivolumab) may be a safe and effective option to halt disease progression in patients with classical Hodgkin’s lymphoma (cHL) who previously achieved disease remission with the treatment, a ... Read more

November 26, 2018

Phase 1 Study of BTK Inhibitor in Treating B-cell Blood Cancers Underway, TG Therapeutics Announces

News

A Phase 1 clinical trial, sponsored by TG Therapeutics, is recruiting patients with B-cell lymphoma or leukemia to study the company’s Bruton tyrosine kinase (BTK) inhibitor, TG-1701. The study is enrolling up ... Read more

November 20, 2018

Adcetris-Chemo Combo Gets FDA Approval for First-line Treatment of PTCL

News

The U.S. Food and Drug Administration (FDA) approved Seattle Genetics‘ application requesting that Adcetris (brentuximab vedotin) be used in combination with chemotherapy as a first-line treatment for systemic anaplastic large cell ... Read more

November 16, 2018

Opdivo Plus ASCT Ably Treats Classical Hodgkin’s Lymphoma Patients with Few Options, Study Says

News

Classical Hodgkin’s lymphoma patients who failed to respond to autologous stem cell transplant (patient-derived cells) showed “unprecedented” low relapse rates after being given Opdivo (nivolumab) followed by an allogeneic, or donor-derived, ... Read more

November 14, 2018

Verastem Advances Copiktra for Peripheral T-cell Lymphoma Under LLS Therapy Acceleration Program

News

Aiming to accelerate the development of Copiktra (duvelisib) for treatment of peripheral T-cell lymphoma (PTCL) — an aggressive type of non-Hodgkin’s lymphoma — Verastem has announced a collaboration with the Leukemia & Lymphoma Society (LLS). ... Read more

November 13, 2018

Rituxan Shows Similar Benefit With or Without Chemo in Indolent Lymphomas, Study Finds

News

Using Rituxan (rituximab) as first-line treatment for indolent — or slow-growing — lymphomas leads to similar long-term survival as regimens containing both Rituxan and chemotherapy, a study shows. The approach also eliminated ... Read more

November 12, 2018

FDA Gives Selinexor Fast Track Status for DLBCL Treatment

News

The U.S. Food and Drug Administration has granted fast track status to Karyopharm Therapeutics‘ investigational oral therapy selinexor for people with diffuse large B-cell lymphoma (DLBCL) who have received two or more ... Read more

November 9, 2018

Seattle Genetics Seeks Adcetris Approval as First-Line Combo Treatment for Peripheral T-cell Lymphomas

News

Seattle Genetics has asked the U.S. Food and Drug Administration (FDA) to expand the label for Adcetris (brentuximab vedotin) to be used in combination with chemotherapy as a first-line treatment for patients with ... Read more